Cargando…
Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction
A clear consensus does not exist about whether the initial dose of gemcitabine, an essential anticancer antimetabolite, should be reduced in patients with liver dysfunction. Adult patients with biliary tract or pancreatic cancer were divided into three groups according to whether they had mild, mode...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768397/ https://www.ncbi.nlm.nih.gov/pubmed/26595259 http://dx.doi.org/10.1111/cas.12851 |